Drug intelligence / Profile preview

ps318

Development stage: Unknown
Modality: Small Molecules

Overview

ps318 is a small molecule compound that has been studied in preclinical pharmacokinetic, pharmacodynamic, and toxicity models. It is not an approved pharmaceutical drug and does not appear to have reached clinical development. In preclinical studies, ps318 exhibited low gut permeability as assessed by the in-vitro Caco-2 cell model. A single oral dose pharmacokinetic study conducted on healthy mice was performed to evaluate its properties[8]. No further information regarding its mechanism of action, therapeutic indication, or developer is available from current sources.

Beyond the preview

Go deeper on ps318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ps318.

Explore the full profile